Posts Tagged: pharmaceuticals


Federal Circuit Affirms Dismissal of Celgene’s Hatch-Waxman Suit Against Mylan, Clarifying Venue and Pleading Requirements

On November 5, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Celgene Corp. v. Mylan Pharmaceuticals Inc. affirming a ruling …
By Steve Brachmann
25 days ago 3

Assessing How Much an Alzheimer’s Drug is Worth

On June 7, 2021, the U.S. Food and Drug Administration (FDA) gave the green light to Aducanumab, a drug developed by Biogen to treat early stage Alzheimer’s, …
By Jack Lu
1 month ago 0

China’s New Patent Linkage System: A Guide for Foreign Chinese Patent Holders

In compliance with the Phase One Trade Agreement, China has implemented a patent linkage system in their amended patent law, which became effective June 1, 2021 (Article 76 of the …

Federal Trade Commission Urges SCOTUS to Deny AbbVie Petition

On Wednesday, May 19, the response brief of the Federal Trade Commission (FTC) was filed with the U.S. Supreme Court in AbbVie v. FTC. The petition for …
By Steve Brachmann
6 months ago 0

House Committee Targets AbbVie Patent Practices, Urges FTC to Investigate

Yesterday, Representatives Carolyn Maloney (D-NY), Jerrold Nadler (D-NY) and David Cicilline (D-RI) asked Federal Trade Commission (FTC) Acting Chair Rebecca Kelly Slaughter to open a formal inquiry …
By Eileen McDermott
7 months ago 7

Waiving IP Rights During Times of COVID: A ‘False Good Idea’

Over the course of four months, close to 850 million doses of COVID-19 vaccines have been administered in over 100 countries. To the extent the unprecedented pace of research, …
By Hans Sauer
8 months ago 37

Bills to Lower Prescription Drug Costs and Boost Biosimilars Sent to Biden’s Desk

The U.S. House of Representatives yesterday approved two bills meant to lower prescription drug prices and sent them on to President Joe Biden for approval. The …
By Eileen McDermott
8 months ago 1

Industry Comments on Proposed Changes to Bayh-Dole Regulations Zero in on March-In Language

On January 12, the National Institute of Standards and Technology (NIST) published a request for comments on proposed changes to regulations that support the University and Small Business …
By Gene Quinn
8 months ago 0

Pfizer Rejects Accusations it Infringed COVID-19 Vaccine Assay Technology

Pfizer and BioNTech have hit back at Allele Biotechnology and Pharmaceuticals, Inc.’s October 2020 complaint accusing the COVID-19 vaccine manufacturers of infringing Allele’s U.S. patent …
By La'Cee Conley
10 months ago 2

Should the Biden Administration Look to Pharma for New USPTO Director?

The United States is not even two weeks into the administration of President Joe Biden and it’s likely that the administration’s selection for Director of …
By Steve Brachmann
10 months ago 7

Calls for WTO to Suspend IP Rights for Vaccine Innovation Would Jeopardize Incredible Progress

The biggest vaccination effort in the history of medicine is underway to eradicate the global pandemic, with several strong prospects appearing poised for regulatory approval. As of …
By Patrick Kilbride
12 months ago 10

A Misguided Op-Ed, a Key Report, and Why Holding the U.S. Lead in the Life Sciences is More Important Than Ever

Our current experiences with COVID-19 in the United States, together with headlines warning of major efforts by the Chinese and Russian governments to hack corporate, academic and …
By Joseph Allen
1 year ago 6

IP Valuation for the Preservation of Public Health: Managing IP in the Age of COVID-19

Certainly, patents that read on a potential cure for COVID-19 deserve special treatment. After all, the cure for COVID-19 is not only crucial to save lives all …
By Roya Ghafele
1 year ago 0

WHO’s C-TAP Initiative Pushes for Non-Exclusive Global Licensing Amid Pharma Industry Concerns

On Friday, May 29, the World Health Organization (WHO) officially launched the COVID-19 Technology Access Pool (C-TAP), an initiative which is intended to improve access to treatments, vaccines …
By Steve Brachmann
2 years ago 2

Efforts to Villainize Biotech, Pharma over COVID-19 are Political Theater and Opportunism

If the objective is to beat this virus as fast as possible it simply isn’t helpful to talk about the compulsory licensing of drugs that don’…
By Gene Quinn
2 years ago 11